Identification of SEC61G as a Diagnostic and Prognostic Biomarker in Oral Squamous Cell Carcinoma

Zhang, Shi-Long; Chen, Lei; Bu, Lin-Lin; Yu, Zi-Li; Ma, Si-Rui

doi:10.3390/biomedicines11102718

Open AccessArticle

Identification of SEC61G as a Diagnostic and Prognostic Biomarker in Oral Squamous Cell Carcinoma

by

Shi-Long Zhang

^1,2,†,

Lei Chen

^1,†,

Lin-Lin Bu

^1,3

,

Zi-Li Yu

^1,3,*

and

Si-Rui Ma

^1,3,*

¹

State Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, Key Laboratory of Oral Biomedicine Ministry of Education, Hubei Key Laboratory of Stomatology, School & Hospital of Stomatology, Wuhan University, Wuhan 430079, China

²

Department of Oral and Maxillofacial Surgery, Dongfeng Stomatological Hospital, Hubei University of Medicine, Shiyan 442000, China

³

Department of Oral and Maxillofacial-Head and Neck Oncology, School and Hospital of Stomatology, Wuhan University, Wuhan 430079, China

^*

Authors to whom correspondence should be addressed.

^†

These authors contributed equally to this work.

Biomedicines 2023, 11(10), 2718; https://doi.org/10.3390/biomedicines11102718

Submission received: 5 September 2023 / Revised: 28 September 2023 / Accepted: 2 October 2023 / Published: 6 October 2023

(This article belongs to the Special Issue Targeting Transcription Factors and Oncogenic Proteins for Cancer Therapy (2nd Edition))

Download

Browse Figures

Versions Notes

Abstract

Oral squamous cell carcinoma (OSCC) is a heterogeneous malignancy originating from the oral mucosal epithelium. Detecting novel biomarkers can offer crucial information on disease aggressiveness and expected clinical outcomes for individual patients. SEC61G, an aberrantly expressed gene in various cancers, has been associated with negative clinical outcomes. However, its expression and clinical significance in OSCC is still unclear. In the present study, we investigated the SEC61G expression level in OSCC using bioinformatic and immunohistochemical analyses. Additionally, our findings revealed a significant correlation between SEC61G expression and clinicopathological characteristics, as well as a worse prognosis in OSCC patients. Notably, flow cytometry analysis on patient samples revealed that SEC61G expression was also linked to decreased immune infiltration in OSCC patients. In conclusion, our study provides evidence supporting SEC61G’s role as a potential diagnostic, prognostic, and therapeutic marker in OSCC.

Keywords: oral squamous cell carcinoma; SEC61G; prognosis; immune infiltration

Share and Cite

MDPI and ACS Style

Zhang, S.-L.; Chen, L.; Bu, L.-L.; Yu, Z.-L.; Ma, S.-R. Identification of SEC61G as a Diagnostic and Prognostic Biomarker in Oral Squamous Cell Carcinoma. Biomedicines 2023, 11, 2718. https://doi.org/10.3390/biomedicines11102718

AMA Style

Zhang S-L, Chen L, Bu L-L, Yu Z-L, Ma S-R. Identification of SEC61G as a Diagnostic and Prognostic Biomarker in Oral Squamous Cell Carcinoma. Biomedicines. 2023; 11(10):2718. https://doi.org/10.3390/biomedicines11102718

Chicago/Turabian Style

Zhang, Shi-Long, Lei Chen, Lin-Lin Bu, Zi-Li Yu, and Si-Rui Ma. 2023. "Identification of SEC61G as a Diagnostic and Prognostic Biomarker in Oral Squamous Cell Carcinoma" Biomedicines 11, no. 10: 2718. https://doi.org/10.3390/biomedicines11102718

APA Style

Zhang, S.-L., Chen, L., Bu, L.-L., Yu, Z.-L., & Ma, S.-R. (2023). Identification of SEC61G as a Diagnostic and Prognostic Biomarker in Oral Squamous Cell Carcinoma. Biomedicines, 11(10), 2718. https://doi.org/10.3390/biomedicines11102718

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Menu

Identification of SEC61G as a Diagnostic and Prognostic Biomarker in Oral Squamous Cell Carcinoma

Abstract

Share and Cite

Article Metrics

Article Access Statistics

Further Information

Guidelines

MDPI Initiatives

Follow MDPI